The effect of NELL1 and bone morphogenetic protein-2 on calvarial bone regeneration.

The effect of NELL1 and bone morphogenetic protein-2 on calvarial bone regeneration.
复制标题

DOI:
10.1016/j.joms.2009.03.066
复制
发表时间:
2010-02
期刊:
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
影响因子:
--
通讯作者:
Zhang Z
Zhang Z
中科院分区:
其他
文献类型:
--
作者:
Aghaloo T;Cowan CM;Zhang X;Freymiller E;Soo C;Wu B;Ting K;Zhang Z

文献摘要

参考文献

被引文献

相似文献

Most craniofacial birth defects contain skeletal components that require bone grafting. Although many growth factors have shown potential for use in bone regeneration, bone morphogenetic proteins (BMPs) are the most osteoinductive. However, supraphysiologic doses, high cost, and potential adverse effects stimulate clinicians and researchers to identify complementary molecules that allow a reduction in dose of BMP-2. Because NELL1 plays a key role as a regulator of craniofacial skeletal morphogenesis, especially in committed chondrogenic and osteogenic differentiation, and a previous synergistic mechanism has been identified, NELL1 is an ideal molecule for combination with BMP-2 in calvarial defect regeneration. We investigated the effect of NELL1 and BMP-2 on bone regeneration in vivo. BMP-2 doses of 589 and 1,178 ng were grafted into 5-mm critical-sized rat calvarial defects, as compared with 589 ng of NELL1 plus 589 ng of BMP-2 and 1,178 ng of NELL1 plus 1,178 ng of BMP-2, and bone regeneration was analyzed. Live micro–computed tomography data showed increased bone formation throughout 4 to 8 weeks in all groups but a significant improvement when the lower doses of each molecule were combined. High-resolution micro–computed tomography and histology showed more mature and complete defect healing when the combination of NELL1 plus BMP-2 was compared with BMP-2 alone at lower doses. The observed potential synergy has significant value in the future treatment of patients with craniofacial defects requiring extensive bone grafting that would normally entail extraoral autogenous bone grafts or doses of BMP-2 in milligrams.
DOI: 10.1016/j.joms.2005.08.018
发表时间: 2005-12-01
影响因子: 1.9
作者:
Boyne, PJ;Lilly, LC;Triplett, RG
通讯作者: Triplett, RG
DOI: 10.1097/00001665-199807000-00004
发表时间: 1998-07-01
影响因子: 0.9
作者:
Bosch, C;Melsen, B;Vargervik, K
通讯作者: Vargervik, K
DOI: 10.1038/10473
发表时间: 1999-07-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Bonadio, J;Smiley, E;Goldstein, S
通讯作者: Goldstein, S
DOI: 10.1210/en.2003-0273
发表时间: 2003-12-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
Chan, GK;Miao, DS;Goltzman, D
通讯作者: Goltzman, D
DOI: 10.1038/sj.mt.6300270
发表时间: 2007-10-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Aghaloo, Tara;Jiang, Xinquan;Zhang, Xinli
通讯作者: Zhang, Xinli